成长期企业融资困局待解 "C轮死"魔咒背后存四大症结 "以前总说'C轮死'，没想到这么多年过去，这个魔咒还是没被打破。"近期一位投资人的 感慨，戳中了成长期创业企业的集体痛点。 在创投市场，如今已呈现哑铃式融资格局：早期项目靠技术故事吸引资本，成熟期企业 凭稳定业绩冲击IPO，而成长期企业却卡在一个"中间地带"：既没了早期估值的吸引力， 又还没具备成熟期的流动性与"造血"能力，融资难成为横在它们面前的一道鸿沟。这道 鸿沟为何迟迟难以填平？有何破局之道？值得整个行业静下心来深思。 B轮成了"融资坎" "去年我们看了约200个成长期项目，没有一个能达到我们的投资安全边际，最终一个都 没法出手。"融创投资创始合伙人赵俊峰无奈说道。在他看来，所谓的"投资安全边际"， 即企业拥有正向经营现金流，而非账面上不断累积的应收账款与大量存货，不然就不是 高质量增长的表现。 华南一券商资深投行人士解枫（化名）对此有同感："我接触过不少这类卡在中间的企 业。比如一家做非侵入式脑机接口的公司，产品性能已达标，但偏偏卡在商业化落地很 难推进，没有医疗渠道和经销商资源，量产又需要大额预付资金，资金压力陡增。结果 就是B轮之后，早期投资人 ...

Group 1 - The core viewpoint of the article is that Beilu Pharmaceutical holds a significant stake in Yiwei Medical, which is a leading AI company in China focused on brain diseases, covering the entire process from screening to diagnosis and rehabilitation [1] - Beilu Pharmaceutical currently owns 14.9881% of Yiwei Medical, making it the second-largest shareholder [1] - Yiwei Medical specializes in non-invasive brain-machine interfaces, neuroregulation, and medical AI, targeting essential scenarios such as stroke, Alzheimer's disease, and cognitive disorders [1]

Summary of Key Points from the Conference Call Industry Overview - The conference call focused on the **brain-computer interface (BCI)** technology, which is categorized into invasive, semi-invasive, and non-invasive types, each with its own advantages and disadvantages [1][3][4]. Core Insights and Arguments - **Non-invasive BCIs** are primarily used for typing communication (based on P300), device control (based on SSVEP), and rehabilitation training (based on motor imagery potentials). However, they face limitations due to skull interference, resulting in low amplitude brain waves and a need for improved decoding accuracy [1][11][13]. - **Invasive BCIs** have made progress in motor and language decoding, as well as visual and auditory reconstruction, but they carry risks such as bleeding, infection, and device reliability issues, leading to uncertainty in commercialization prospects [1][15]. - A research team is exploring a hybrid approach combining **EEG and EMG** to decode motor intentions by analyzing weak muscle signals, which has shown success in helping patients with arm injuries and strokes regain some limb function, with plans for commercial use by mid-2025 [1][16][17]. - The market potential for hand function rehabilitation in China is significant, with over **50 million** patients suffering from limb disabilities and an annual increase of **2 to 3 million** cases [1][18]. Additional Important Content - The **clinical application** of EEG differs from BCI research, requiring higher sampling rates (1,000 Hz to 20,000 Hz) for effective data quality in BCI applications compared to the lower rates used in clinical settings [2]. - The **hardware segment** of the BCI industry has high barriers to entry and substantial profit margins, making it a promising investment area, especially in the context of China's healthcare payment habits [24]. - **Neuralink**, a prominent player in the invasive BCI space, has raised questions about its valuation and the practical benefits of its technology compared to non-invasive alternatives [23][22]. - The **supply chain** for BCI products is influenced by the compatibility of cost control and healthcare payment systems, particularly for non-invasive rehabilitation and invasive surgeries [24]. - Future applications of BCI technology may extend to treating mental health disorders and cognitive enhancement, although these areas still face significant challenges in decoding complex brain functions [26]. This summary encapsulates the key points discussed in the conference call, highlighting the current state and future potential of brain-computer interface technology.

Group 1 - The company held an investor meeting on January 4, 2026, to discuss business progress, performance planning, and technology layout with institutional investors [1] - Key participants included the company's Vice General Manager and Board Secretary, Investment Director, and heads of various departments [1] Group 2 - The joint venture company is focused on developing next-generation edge brain-machine interface algorithm chips and advancing mixed biometric and brain signal analysis [2] - The joint venture is currently in the process of business registration [2] Group 3 - The company has set its 2026 performance targets based on the 2025 restricted stock incentive plan and employee stock ownership plan [3] - To achieve these targets, the company plans to leverage AI technology, enhance brand influence, and expand market space [3] Group 4 - The performance assessment for the stock incentive plan excludes results from acquisitions, focusing instead on the company's organic growth capabilities [4] Group 5 - The company's non-invasive brain-machine business leverages long-term AI cognitive computing expertise, focusing on BioCV TinyML edge model development [5] - This approach aims to optimize brain-machine interaction across various elements by integrating perception, analysis, and decision-making capabilities into edge devices [5] Group 6 - The partnership with ShenNian Technology is based on its 20 years of industry experience, strong data accumulation, and a cross-disciplinary team [6] - ShenNian's business model, which combines chips and algorithm SDKs, has been successfully validated [6] Group 7 - The company has not yet adopted digital RMB for cross-border settlements and is managing exchange rate risks through global supply chain strategies and local operations [7] - The company employs various methods to hedge against currency risks, including forward foreign exchange contracts and attempts at cross-border RMB settlements [7]

Group 1: Company Overview and Business Focus - The company is focused on developing next-generation edge brain-machine interface algorithm chips and advancing mixed biometric and brain signal collaborative analysis [2] - The joint venture is currently in the preparation stage for business registration [2] Group 2: Performance Guidance and Targets - The company has set performance assessment targets for 2026 based on the 2025 restricted stock incentive plan and employee stock ownership plan [2] - Strategies to achieve growth include deepening technology applications, expanding market reach, enhancing brand influence, and increasing product and service competitiveness [2] Group 3: Incentive Plan and Acquisitions - The stock incentive plan specifies that the operating results of newly acquired companies will not be included in the performance assessment during the incentive period [3] - The impact of these acquisitions on the company's net profit and operating income will be calculated separately [3] Group 4: Competitive Advantages - The company leverages long-term accumulation in cognitive space computing and focuses on AI BioCV TinyML edge model development [3] - The integration of perception, analysis, and decision-making capabilities into edge devices establishes a solid technical foundation for wearable and scenario-based applications of non-invasive brain-machine interfaces [3] Group 5: Team Strengths and Market Position - The team has extensive experience in the industry, with a strong data accumulation in consumer scenarios and a stable performance indicator [3] - The founding and R&D team includes members from Silicon Valley and renowned U.S. institutions, covering multiple fields such as chip design and algorithm development [3] Group 6: Currency and Risk Management - The company has not yet adopted digital RMB for cross-border settlements, and foreign income constitutes a significant portion of its revenue [3] - To mitigate currency fluctuation risks, the company employs global supply chain strategies and local operations of subsidiaries, along with forward foreign exchange contracts [3]

Core Insights - The brain-computer interface (BCI) industry in China has entered a critical phase of "clinical value verification and early industrialization" with significant policy support and upcoming major conferences [2][3][4] - The industry is characterized by three parallel paths: "invasive" breakthroughs, "non-invasive" popularization, and "semi-invasive" exploration, with a focus on integrating AI with non-invasive technologies [7][8] - The market for brain-computer interfaces is expected to reach 5.58 billion yuan by 2027, with a growth rate of 20% as applications expand beyond healthcare into various sectors [7] Industry Developments - The "2025 Brain-Computer Interface Conference" will take place in Shanghai on December 4-5, featuring competitions that demonstrate the transition of BCI technology from laboratory to application [3] - Following this, additional conferences in Hangzhou and Shenzhen will further explore BCI applications and innovations [3] - The industry is transitioning from a focus on technical novelty to meeting specific clinical needs and establishing quantifiable clinical endpoints [4] Technological Landscape - BCI technology is categorized into three types: invasive, non-invasive, and semi-invasive, with non-invasive methods being the mainstream due to their safety and ease of use [5][6] - Invasive methods are seen as the future competitive edge due to their ability to capture higher quality neural signals, essential for functional restoration [6][7] - AI is opening new commercial opportunities for non-invasive BCIs, particularly in diagnosing and monitoring brain diseases [6][7] Challenges and Solutions - The BCI industry faces a "technology-cost-ethics" triangle dilemma, requiring solutions that address technical challenges, cost reduction, and ethical concerns regarding data privacy [8][9] - Proposed solutions include developing a data governance framework, promoting open-source communities for algorithm development, and creating collaborative networks among government, industry, academia, and medical sectors [9]

Group 1 - The core viewpoint emphasizes the importance of technological innovation in driving industrial innovation and developing new productive forces in Tianjin [1][2] - Nankai University's research team has developed perovskite solar cells that address issues of short battery life and high costs, while also improving stability in high-temperature environments [1] - Tianjin University’s neuroengineering team has focused on non-invasive brain-computer interfaces, achieving significant technological breakthroughs over a decade [1] Group 2 - Galileo (Tianjin) Technology Co., Ltd. has developed a digital twin intelligent operation and maintenance platform that serves over 85% of national rail transit lines, enhancing safety and efficiency in train operations [2] - The Tianjin High Education Science and Technology Innovation Park has incubated over 3,900 enterprises, reflecting nearly double growth in national key laboratories and sustained high R&D investment intensity [2] - The development of new productive forces in Tianjin is aligned with the goal of improving the quality of life for citizens, showcasing a commitment to transforming technological breakthroughs into tangible benefits [2]

Core Insights - Brain-computer interface (BCI) technology is transitioning from laboratory research to practical applications, establishing a connection between the human brain and the digital world [1][2] - The Chinese government has identified BCI as a key emerging industry in its 14th Five-Year Plan, aiming to foster new economic growth points over the next decade [1][3] - Various cities, including Shanghai, Beijing, and Shenzhen, are actively developing BCI industry clusters to accelerate the technology's growth and application [3][10] Industry Development - BCI technology enables direct communication between the brain and external devices, bypassing peripheral nerves and muscles [2] - The technology is categorized into three types: invasive, semi-invasive, and non-invasive, with invasive BCI primarily used in medical scenarios [2][4] - Shanghai's action plan aims for BCI to become a core component of strategic emerging industries by 2030, targeting a market scale of hundreds of billions to trillions [3][10] Clinical Applications - BCI is showing promise in medical applications, particularly in rehabilitation and recovery for patients with motor and speech impairments [4][6] - Clinical trials have demonstrated successful applications of invasive BCI in restoring functions for patients with severe disabilities, such as those resulting from high-voltage accidents [6][7] - Non-invasive BCI technologies are being developed to provide less risky treatment options for conditions like depression and eating disorders [6][7] Technological Innovations - New advancements in BCI technology include wireless, minimally invasive systems that avoid direct damage to neural cells while providing reliable communication with the brain [7][9] - Companies are exploring innovative solutions for visual restoration using BCI, aiming to help patients with severe vision loss regain some level of sight [8][9] - Collaborative efforts among academic institutions and companies are enhancing the development of BCI technologies, focusing on personalized treatment approaches for neurological disorders [10]

Core Viewpoint - The article highlights the significant role of insurance capital in supporting technological innovation and the development of the "Six Little Dragons" in Hangzhou, showcasing a shift from traditional investment to a more integrated approach that combines capital with services [1][5][9]. Group 1: Investment Landscape - The "Six Little Dragons" of Hangzhou include several innovative tech companies that have attracted attention from capital markets, with plans for some to go public [2][3]. - Major insurance companies like China Life and Pacific Insurance are using indirect investment methods, becoming financial backers through a multi-layered investment structure involving private equity funds [2][3]. - Insurance capital has invested over 600 billion yuan in technology enterprises, reflecting a growing commitment to supporting the entire lifecycle of tech companies [5][6]. Group 2: Investment Models - Insurance funds primarily participate as limited partners in private equity funds, often collaborating with government or state-owned funds to invest in technology firms [4][5]. - The investment approach of insurance capital has evolved to include a mix of indirect equity investments and direct funding, aiming to balance safety and strategic value [4][8]. - The establishment of funds like the National SME Development Fund illustrates how insurance capital is leveraging government-led initiatives to invest in technology [3][4]. Group 3: Challenges and Solutions - Insurance capital faces challenges in aligning its traditional investment strategies with the high-risk, high-reward nature of technology innovation [7][8]. - To address these challenges, insurance asset management companies are innovating their investment models, such as using S-funds to better match long-term insurance capital with the needs of tech innovation [7][8]. - The shift towards a more proactive role as "active capital" reflects a broader trend of insurance funds becoming integral partners in the technology sector, moving beyond mere financial investors [9].

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by recent policy support and technological advancements, with several companies in the field seeing substantial stock price increases. Group 1: Company Performance - QiSheng Technology (麒盛科技) saw its stock price rise by 10.01% to 14.40, with a market capitalization of 5.08 billion, focusing on sleep-related technologies and brain-machine interaction [2] - Innovation Medical (创新医疗) increased by 9.99% to 20.59, with a market cap of 8.57 billion, holding a 40% stake in BoLing Brain-Machine Technology, which is developing core BCI technologies [2] - Xiangyu Medical (翔宇医疗) surged by 13.72% to 65.97, with a market cap of 10.56 billion, having completed several key projects in the BCI field and holding numerous patents [2] - Chengpin Technology (诚品通) rose by 8.60% to 23.23, with a market cap of 6.04 billion, collaborating with Tsinghua University on both non-invasive and invasive BCI technologies [2] Group 2: Industry Developments - On August 7, the Ministry of Industry and Information Technology and six other departments released guidelines to promote BCI innovation, aiming for breakthroughs in key technologies by 2027 [3] - The establishment of the Hubei BCI Industry Innovation Development Alliance was announced on August 9, indicating a collaborative effort to advance the sector [3] - The 2025 World Robot Competition showcased non-invasive BCI products for nerve injury treatment, highlighting the practical applications of BCI technology [3] Group 3: Institutional Insights - The guidelines emphasize the establishment of an advanced technology, industry, and standard system for BCI by 2027, with expectations for BCI applications in healthcare, rehabilitation, and skill replacement [4] - BCI technology is positioned at the intersection of life sciences and information sciences, facilitating collaboration between biological and machine intelligence [4] - Various provinces and cities in China are implementing policies to support BCI development, with significant potential for commercialization in healthcare and other sectors [5]